glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 receptor agonists and next-generation
Pay in 4 interest-free payments of $6.79 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 receptor agonists and next-generation](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41581-025-01036-y/MediaObjects/41581_2025_1036_Fig1_HTML.png)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 receptor agonists and next-generation](https://www.frontiersin.org/api/ipx/f=webp/https://www.frontiersin.org/files/Articles/1590530/xml-images/fcdhc-06-1590530-g000.webp)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 receptor agonists and next-generation](https://www.datocms-assets.com/92605/1713817602-featured-image.png?auto=format&q=65)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 receptor agonists and next-generation](https://www.teachmepharmacy.info/wp-content/uploads/2025/10/AdobeStock_577004646-scaled.jpeg)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 receptor agonists and next-generation](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6b5/12668736/ebe855f1bb0e/ofa-2025-0018-0006-546472_F01.jpg)



















